Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - Section for Experimental Cancer Treatment
14 publications found
Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver
Br J Surg, 106 (1), 132-141
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
Clin Chim Acta, 487, 107-111
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Eur J Cancer, 101, 236-243
Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma
Br J Surg, 105 (6), 736-742
Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver
BJS Open, 3 (2), 180-185
Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation
Nucl Med Commun, 39 (7), 621-627
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
The Potential Role of Liver Transplantation as a Treatment Option in Colorectal Liver Metastases
Can J Gastroenterol Hepatol, 2018, 8547940
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
Ann Oncol, 29 (3), 758-765
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Eur J Cancer, 94, 156-167
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876